Hypercalcemia Treatment Market is anticipated to rise at a value CAGR of 11.09% over 2019-2028. According to a study published by Insure Insights on the Hypercalcemia Treatment Market, Hypercalcemia refers to the increased level of calcium in the blood when it is above the normal level. The increased level of calcium in the blood is subjected to weaken bones, create kidney stones, and interfere with the working of the heart and brain. The rise in the capita income, the prevalence of Hyperthyroidism related to Hypercalcemia are driving the market growth

Top Driver: Availability of combination therapy in the treatment of Hypercalcemia is making a crucial contribution to the market

Combination therapy is much preferred in the case of Hypercalcemia; it mostly includes the combination of glucocorticosteroid drugs, oral phosphates, it leads to forced diuresis, i.e., calcium is removed out through the urine is utilized to take advantage of multiple mechanisms of action. There are various advanced treatments to control Hypercalcemia. The rise in the incidence of cancer globally, the surging number of cancer patients, is expanding the market growth. Government spending’s for better healthcare, and increased R&D expenditure is further escalating the growth of the market

Bisphosphates to rule the Market Growth of Global Hypercalcemia Treatment Market

Biophasphates are the most preferred drug in the treatment of Hypercalcemia, as they inhibit osteoclastic bone resorption and make it very effective in the treatment of Hypercalcemia; it leads to causing increased bone resorption and malignancy-related Hypercalcemia. Pamidronate and etidronate are the bio phosphates given intravenously. In terms of Route of administration, Intravenous treatment is mostly preferred in severe cases. Based on the End User hospitals have obtained the highest growth due to the developed healthcare infrastructure in the hospitals

Rising incidences of Hyperthyroidism benefit the North American Market  

North America has witnessed an increase in the cases of Hyperthyroidism, an increase in cases of Hypercalcemia due to Hyperthyroidism is on the rise and is thus boosting the growth of the market, moreover enhanced healthcare facilities, increase in the per capita income, are expanding market growth. Government funding’s and an increase in the R&D expenditure are further driving the growth of the regional market. North America has a High prevalence of malignancy-related Hypercalcemia, and the rise in the awareness of the disease in the regions is a major factor for the growth. The rise in The technological advances in the healthcare is further boosting the regional growth.

Strategic collaboration and acquisition, new product launches are the major strategies of the competitors

The market of the global Hypercalcemia market is highly fragmented. The market players focus on Strategic collaboration and acquisition, new product launches, joint partnerships are the strategies used by the competitors for their overall growth. The key competitors of the Global Hypercalcemia treatment market are Fujirebio, DIASORIN S.p. A, AstraZeneca, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Novartis AG, AbbVie Inc. Bayer AG, and Pfizer Inc.,

Pfizer Inc: Pfizer Inc. is a giant competitor of the global Hypercalcemia Treatment market. For instance, in the year 2019, Pfizer Inc. and Array BioPharma Inc had announced that they both have entered into a definitive merger agreement, under which Pfizer will acquire Array, a commercial-stage biopharmaceutical company. Array is very much focused on the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases. The acquisition was made for USD 11.4 billion.

Bayer AG : Bayer AG, is one of the popular competitors of the global Hypercalcemia Treatment Market. Bayer had successfully completed the biggest acquisition in its history in the year 2018, The acquisition was done for USD 63 billion, the acquisition with Monsanto was made so as to strengthen position in the agricultural industry. This was the strongest portfolio of seed and crop protection products as it provides a wide range of crops and indications, the best research and development platform, and has also helped in leading digital farming business.

Scope of the Report

By Route of Administration

• Oral
• Intravenous

By Drug Class

• Bisphosphonates
• Calcitonin
• Denusomab
• Glucocorticoids

By End-User

• Hospitals
• Clinics

By Region

• North America
• Europe
• Asia Pacific
• LAMEA